Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Summary from the CNBC news feed. Copyright belongs to CNBC.
Opens in a new tab, so Investz stays open.
Headlines and summaries come from publishers’ public news feeds and are shown with attribution and a link to the original. Investz does not write or endorse them and they are not investment advice. Disclosures.